Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Invested Capital (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Invested Capital for 7 consecutive years, with $369.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 33.27% to $369.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $369.0 million, a 33.27% decrease, with the full-year FY2024 number at $510.6 million, up 65.87% from a year prior.
  • Invested Capital was $369.0 million for Q3 2025 at 4D Molecular Therapeutics, down from $420.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $600.6 million in Q1 2024 to a low of $218.6 million in Q1 2023.
  • A 5-year average of $356.4 million and a median of $319.1 million in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 385.07% in 2021, then crashed 33.27% in 2025.
  • 4D Molecular Therapeutics' Invested Capital stood at $319.1 million in 2021, then decreased by 27.5% to $231.3 million in 2022, then soared by 33.07% to $307.8 million in 2023, then skyrocketed by 65.87% to $510.6 million in 2024, then decreased by 27.74% to $369.0 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Invested Capital are $369.0 million (Q3 2025), $420.9 million (Q2 2025), and $469.7 million (Q1 2025).